Covalon Technologies

COV-X

Analysis and Opinions about COV-X

Signal
Opinion
Expert
PAST TOP PICK
PAST TOP PICK
September 19, 2019
(A Top Pick Aug 08/18, Down 78%) They had a $100 million contract from the Middle East, but the revenue in the deal has been delayed. COV had huge promise and now it's Show Me The Money. The revenue delay is hurting them. Also, they had a recent stock issuance. But insiders still own a big chunk of this.
Covalon Technologies (COV-X)
September 19, 2019
(A Top Pick Aug 08/18, Down 78%) They had a $100 million contract from the Middle East, but the revenue in the deal has been delayed. COV had huge promise and now it's Show Me The Money. The revenue delay is hurting them. Also, they had a recent stock issuance. But insiders still own a big chunk of this.
Peter Hodson
CEO & Head of Research, 5i Research Inc.
Price
$2.050
Owned
Yes
WEAK BUY
WEAK BUY
August 8, 2019
Bandages and dressings / wound care. They made a few miss-steps recently. An overseas issue has been addressed. They signed some agreements overseas and the revenue is not yet coming in. Even if the contracts don't generate cash flows, it is already in the stock, but if money comes in there could be upside from it. They are working in other areas as well. He likes the trade-off
Bandages and dressings / wound care. They made a few miss-steps recently. An overseas issue has been addressed. They signed some agreements overseas and the revenue is not yet coming in. Even if the contracts don't generate cash flows, it is already in the stock, but if money comes in there could be upside from it. They are working in other areas as well. He likes the trade-off
Ryan Modesto
Managing Partner, 5i Research
Price
$2.100
Owned
Yes
WATCH
WATCH
August 1, 2019
He does not own this bio-tech company. He just does not follow it enough currently to comment. Management has changed so he hopes it will improve things.
He does not own this bio-tech company. He just does not follow it enough currently to comment. Management has changed so he hopes it will improve things.
Robert McWhirter
President, Selective Asset Management
Price
$2.200
Owned
No
WATCH
WATCH
June 19, 2019
They make bandage products. They are developing new products all the time. A big contract in the Middle East is creating a chunky quarter result and raising concerns about Saudi Arabia geopolitics. Over the next six months revenues should increase so you want to watch for a while.
They make bandage products. They are developing new products all the time. A big contract in the Middle East is creating a chunky quarter result and raising concerns about Saudi Arabia geopolitics. Over the next six months revenues should increase so you want to watch for a while.
Ryan Modesto
Managing Partner, 5i Research
Price
$4.540
Owned
Unknown
SPECULATIVE BUY
SPECULATIVE BUY
February 20, 2019
He likes their potential, especially with a $100 million project in the Middle East (although Canada's relation with Saudi Arabia is strained). They make wound bandages and compete against companies like Johnson&Johnson. This should be a good year. They are debt free and are expanding their business in the US. He would endorse the management team. It is a speculative buy until they can bring forward more contracts to monetize their cash flow.
He likes their potential, especially with a $100 million project in the Middle East (although Canada's relation with Saudi Arabia is strained). They make wound bandages and compete against companies like Johnson&Johnson. This should be a good year. They are debt free and are expanding their business in the US. He would endorse the management team. It is a speculative buy until they can bring forward more contracts to monetize their cash flow.
Peter Hodson
CEO & Head of Research, 5i Research Inc.
Price
$5.020
Owned
Yes
COMMENT
COMMENT
November 29, 2018
Essentially health care dressing, bandages and things like that. They have a big entrance into the market when they won a big contract in Saudi Arabia but now there are concerns with all the problems with that country. They have a foot on the US side now as well. Revenue is very good. It is high risk as it is a small name.
Essentially health care dressing, bandages and things like that. They have a big entrance into the market when they won a big contract in Saudi Arabia but now there are concerns with all the problems with that country. They have a foot on the US side now as well. Revenue is very good. It is high risk as it is a small name.
Ryan Modesto
Managing Partner, 5i Research
Price
$5.570
Owned
Unknown
BUY
BUY
November 15, 2018
He considers it a quality company and worth owning. He likes the balance sheet and the product. The management company has sold companies before. Put it away and don’t look at it on a daily basis.
He considers it a quality company and worth owning. He likes the balance sheet and the product. The management company has sold companies before. Put it away and don’t look at it on a daily basis.
Peter Hodson
CEO & Head of Research, 5i Research Inc.
Price
$5.790
Owned
Unknown
TOP PICK
TOP PICK
August 3, 2018

This company makes wound dressings for medical devices and just won a $100 million contract overseas. Earnings growth is going to massively accelerate with the new contract. He wants to see them get another contract and they have good potential for growth in Europe. Yield 0%.

This company makes wound dressings for medical devices and just won a $100 million contract overseas. Earnings growth is going to massively accelerate with the new contract. He wants to see them get another contract and they have good potential for growth in Europe. Yield 0%.

Peter Hodson
CEO & Head of Research, 5i Research Inc.
Price
$9.150
Owned
Yes
BUY
BUY
May 8, 2018

They make medical supplies, signed a large contract recently and are doing well. They compete successfully with companies like 3M overseas. The stock is not very liquid because there is one very large owner. It has risen recently, but if you own it, you should hang onto it. They surprise people with good news, which shows up in the stock price.

They make medical supplies, signed a large contract recently and are doing well. They compete successfully with companies like 3M overseas. The stock is not very liquid because there is one very large owner. It has risen recently, but if you own it, you should hang onto it. They surprise people with good news, which shows up in the stock price.

Fabrice Taylor
Publisher, The President's Club Newsletter
Price
$6.170
Owned
Unknown
COMMENT
COMMENT
November 16, 2017

It is not a well known name at all. It is medical products. One investor owns close to a half of it. They are gaining market share. He is guessing they are a takeout play at some point.

It is not a well known name at all. It is medical products. One investor owns close to a half of it. They are gaining market share. He is guessing they are a takeout play at some point.

Fabrice Taylor
Publisher, The President's Club Newsletter
Price
$4.420
Owned
Unknown
WATCH
WATCH
August 21, 2017

It is quite illiquid. They are a medical supply company that is beating out 3M on a number of contracts. It has a lot of promise. He is looking into it and thinks it will be worth buying.

It is quite illiquid. They are a medical supply company that is beating out 3M on a number of contracts. It has a lot of promise. He is looking into it and thinks it will be worth buying.

Fabrice Taylor
Publisher, The President's Club Newsletter
Price
$2.410
Owned
No
COMMENT
COMMENT
May 15, 2014

Supply every type of thing that a company would need in a hospital such as gowns, etc. These types of businesses tend to be very stable

Supply every type of thing that a company would need in a hospital such as gowns, etc. These types of businesses tend to be very stable

Darren Sissons
Vice President and Partner, Campbell Lee & Ross
Price
$1.640
Owned
Yes
BUY
BUY
March 26, 2008
Has done tremendously well. They focus on wound care products, and coatings for products. The company has tremendous potential, they signed a deal with a large British company. Great opportunity, going to do well going forward.
Has done tremendously well. They focus on wound care products, and coatings for products. The company has tremendous potential, they signed a deal with a large British company. Great opportunity, going to do well going forward.
Geoff Houlton
Senior Healthcare Analyst., Union Securities
Price
$2.640
Owned
Unknown
BUY
BUY
February 13, 2008
An interesting little company. Have a wound care product. Also have intellectual property around coatings, basically silver-based, that prevents infection. As they get more partnerships on the coatings, the stock will move up.
An interesting little company. Have a wound care product. Also have intellectual property around coatings, basically silver-based, that prevents infection. As they get more partnerships on the coatings, the stock will move up.
Howard Sutton
President, Tera Capital Corp.
Price
$3.150
Owned
Yes
BUY
BUY
November 23, 2007
A fantastic success story. Have technology in the wound dressing area. There are also rumours of a big deal coming their way. Fantastic management.
A fantastic success story. Have technology in the wound dressing area. There are also rumours of a big deal coming their way. Fantastic management.
Hugh Cleland, CFA
Founding Portfolio Manager, Northern Rivers Capital Management Inc.
Price
$3.490
Owned
No
Showing 1 to 15 of 16 entries